Trial 3C-23-10


A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for the First-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic, Immunotherapy
Randomized: Yes
USC Satellite Location: USC Koreatown, USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Heinz Josef Lenz, M.D.
Other Trial Staff:  Charlean Ketchens, Coordinator, Jiayi Jiang, D.M., Mary Ordaz, D.M., Noureddine Miloud, D.M., Yanli Wang, D.M., Niranjan Bhatt, D.M., Rabia Rehman, Coordinator, Young-Wook Kim, Coordinator, Diane Chun, Coordinator, Janet Luong, Coordinator, Liza Pizarro, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.